Similar articles for PMID: 33517270

Year	Number of Results
2008	1
2009	2
2010	2
2011	3
2012	6
2013	6
2014	10
2015	15
2016	15
2017	17
2018	18
2019	18
2020	19
2021	11

1

Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.

Papadaki MA, Aggouraki D, Vetsika EK, Xenidis N, Kallergi G, Kotsakis A, Georgoulias V. Papadaki MA, et al. Anticancer Res. 2021 Feb;41(2):661-670. doi: 10.21873/anticanres.14817. Anticancer Res. 2021. PMID: 33517270

2

A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.

Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulias V, Kotsakis A. Vetsika EK, et al. J Immunol Res. 2014;2014:659294. doi: 10.1155/2014/659294. Epub 2014 Nov 11. J Immunol Res. 2014. PMID: 25436215 Free PMC article.

3

EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.

Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. Le Du F, et al. PLoS One. 2020 Mar 26;15(3):e0229903. doi: 10.1371/journal.pone.0229903. eCollection 2020. PLoS One. 2020. PMID: 32214335 Free PMC article.

4

Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.

Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. Papadaki MA, et al. Mol Cancer Ther. 2019 Feb;18(2):437-447. doi: 10.1158/1535-7163.MCT-18-0584. Epub 2018 Nov 6. Mol Cancer Ther. 2019. PMID: 30401696 Free article.

5

Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.

Li F, Zhao Y, Wei L, Li S, Liu J. Li F, et al. Cancer Biol Ther. 2018 Aug 3;19(8):695-705. doi: 10.1080/15384047.2018.1450116. Epub 2018 May 8. Cancer Biol Ther. 2018. PMID: 29621426 Free PMC article.

6

Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP. Liu CY, et al. J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45. doi: 10.1007/s00432-009-0634-0. J Cancer Res Clin Oncol. 2010. PMID: 19572148

7

PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.

Sprouse ML, Welte T, Boral D, Liu HN, Yin W, Vishnoi M, Goswami-Sewell D, Li L, Pei G, Jia P, Glitza-Oliva IC, Marchetti D. Sprouse ML, et al. Int J Mol Sci. 2019 Apr 18;20(8):1916. doi: 10.3390/ijms20081916. Int J Mol Sci. 2019. PMID: 31003475 Free PMC article.

8

Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.

Safarzadeh E, Hashemzadeh S, Duijf PHG, Mansoori B, Khaze V, Mohammadi A, Kazemi T, Yousefi M, Asadi M, Mohammadi H, Babaie F, Baradaran B. Safarzadeh E, et al. J Cell Physiol. 2019 Apr;234(4):3515-3525. doi: 10.1002/jcp.26896. Epub 2018 Oct 26. J Cell Physiol. 2019. PMID: 30362521

9

Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.

Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, McCarter MD. Jordan KR, et al. Cancer Immunol Immunother. 2017 Apr;66(4):503-513. doi: 10.1007/s00262-016-1953-z. Epub 2017 Jan 20. Cancer Immunol Immunother. 2017. PMID: 28108766 Free PMC article.

10

Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.

Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Giordano A, et al. Mol Cancer Ther. 2012 Nov;11(11):2526-34. doi: 10.1158/1535-7163.MCT-12-0460. Epub 2012 Sep 12. Mol Cancer Ther. 2012. PMID: 22973057 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed